BRCA2 and Familial prostate cancer: Ideally, one would follow a cohort of unselected patients with prostate cancer and a BRCA2 mutation, record details on the stage, grade and all treatments received, and then compare the outcome of the hereditary group with a similar group of patients without a mutation.